SeqOnce Biosciences, founded in California, is a life science company dedicated to advancing DNA testing and sample preparation technology. Their core mission is to enhance the accuracy and efficiency of genetic testing through innovative solutions. The company offers a range of products, including qPCR panels for respiratory pathogens, urinary tract microbiota detection, antibiotic resistance gene detection, and NGS DNA library preparation kits like RhinoSeq. SeqOnce Biosciences primarily serves the healthcare and research markets, focusing on providing reliable and rapid diagnostic tools.
Notable affiliated individuals and investors include experts in genomics and biotechnology, though specific names are not publicly highlighted. Key achievements of SeqOnce Biosciences include the development of advanced qPCR panels and the RhinoSeq NGS DNA library prep kit, which have significantly impacted the efficiency of genetic testing processes. The company's contributions have improved diagnostic accuracy and speed, making a substantial impact on healthcare diagnostics and research methodologies.
